Published in Neuropsychopharmacology on November 14, 2007
Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem (2009) 2.70
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull (2010) 1.98
Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron (2014) 1.77
Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol (2013) 1.52
Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev (2010) 1.38
Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry (2010) 1.36
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci (2011) 1.35
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull (2012) 1.33
Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal (2011) 1.32
Using glutamate homeostasis as a target for treating addictive disorders. Behav Pharmacol (2010) 1.31
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One (2012) 1.28
Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology (2009) 1.21
Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacol Rev (2012) 1.21
Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry (2011) 1.20
Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology (2011) 1.19
Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr Bull (2009) 1.14
The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol (2009) 1.12
Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull (2008) 1.10
Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One (2008) 1.08
Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr Res (2014) 1.06
N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology (2011) 1.02
Age-dependent decrease and alternative splicing of methionine synthase mRNA in human cerebral cortex and an accelerated decrease in autism. PLoS One (2013) 1.02
Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage (2012) 1.00
Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res (2014) 1.00
Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review. Front Psychiatry (2013) 0.99
Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry (2014) 0.99
Neurobiology of schizophrenia onset. Curr Top Behav Neurosci (2014) 0.96
Oxidative stress in schizophrenia. Curr Neuropharmacol (2011) 0.96
Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia. Schizophr Bull (2015) 0.95
Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res (2013) 0.94
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci (2016) 0.94
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res (2009) 0.93
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One (2012) 0.90
Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J (2014) 0.90
N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci (2015) 0.90
Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid Redox Signal (2015) 0.89
Mismatch negativity (MMN) as an index of cognitive dysfunction. Brain Topogr (2014) 0.89
The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl) (2010) 0.89
Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci (2011) 0.88
Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci (2015) 0.87
Postmortem brain tissue for drug discovery in psychiatric research. Schizophr Bull (2009) 0.87
Glutathione restores the mechanism of synaptic plasticity in aged mice to that of the adult. PLoS One (2011) 0.86
Echo time optimization for J-difference editing of glutathione at 3T. Magn Reson Med (2016) 0.85
Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Ann N Y Acad Sci (2015) 0.85
Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin (2014) 0.85
Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia. PLoS One (2013) 0.84
A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression. Biol Psychiatry (2015) 0.83
Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med (2012) 0.83
How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia. Antioxid Redox Signal (2012) 0.82
Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophr Bull (2012) 0.81
The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia. Schizophr Res Treatment (2012) 0.80
Redox-based epigenetic status in drug addiction: a potential contributor to gene priming and a mechanistic rationale for metabolic intervention. Front Neurosci (2015) 0.80
Impaired early visual response modulations to spatial information in chronic schizophrenia. Psychiatry Res (2011) 0.80
Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics. Indian J Psychiatry (2014) 0.79
Contributions of experimental psychiatry to research on the psychosis prodrome. Front Psychiatry (2013) 0.78
Oxidative/Nitrosative stress in psychiatric disorders: are we there yet? Schizophr Bull (2014) 0.78
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia. World Psychiatry (2013) 0.78
Yi-gan san restores behavioral alterations and a decrease of brain glutathione level in a mouse model of schizophrenia. J Brain Dis (2009) 0.77
Mechanisms of divalent metal toxicity in affective disorders. Toxicology (2015) 0.76
Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators Inflamm (2016) 0.76
Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Front Behav Neurosci (2017) 0.76
Possible involvement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effects. Exp Biol Med (Maywood) (2015) 0.75
A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Curr Neuropharmacol (2015) 0.75
Preventing, treating, and predicting barbering: A fundamental role for biomarkers of oxidative stress in a mouse model of Trichotillomania. PLoS One (2017) 0.75
Electrochemical Probing through a Redox Capacitor To Acquire Chemical Information on Biothiols. Anal Chem (2016) 0.75
Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats. Psychopharmacology (Berl) (2016) 0.75
Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk. Int J Mol Sci (2017) 0.75
Caenorhabditis elegans as a model system to study post-translational modifications of human transthyretin. Sci Rep (2016) 0.75
Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment. Transl Psychiatry (2016) 0.75
Decreased serum sulphydryl levels as a sign of increased oxidative stress in generalized anxiety disorder. Psychiatry Investig (2013) 0.75
Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Transl Psychiatry (2017) 0.75
Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice. Neuroscience (2016) 0.75
Potential role of amino acids in pathogenesis of schizophrenia. Int J Health Sci (Qassim) (2017) 0.75
Mapping the structural core of human cerebral cortex. PLoS Biol (2008) 16.38
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis (2008) 5.39
The neurobiology of zinc in health and disease. Nat Rev Neurosci (2005) 5.07
Mapping human whole-brain structural networks with diffusion MRI. PLoS One (2007) 4.54
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
EEG source imaging. Clin Neurophysiol (2004) 4.38
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke (2006) 3.49
Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics (2006) 3.37
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
The elephant on the couch: side-effects of psychotherapy. Aust N Z J Psychiatry (2009) 3.31
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
Association of Western and traditional diets with depression and anxiety in women. Am J Psychiatry (2010) 2.99
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics (2005) 2.94
Multisensory auditory-visual interactions during early sensory processing in humans: a high-density electrical mapping study. Brain Res Cogn Brain Res (2002) 2.93
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol (2002) 2.52
Multisensory mechanisms in temporo-parietal cortex support self-location and first-person perspective. Neuron (2011) 2.46
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol (2008) 2.44
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Postcarotid endarterectomy hyperperfusion or reperfusion syndrome. Stroke (2004) 2.36
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Electrical neuroimaging based on biophysical constraints. Neuroimage (2004) 2.29
Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. Arch Gen Psychiatry (2002) 2.18
Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem (2009) 2.13
Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci (2009) 2.12
Dorsal fractures of the triquetrum: MRI findings with an emphasis on dorsal carpal ligament injuries. AJR Am J Roentgenol (2013) 2.12
Auditory-somatosensory multisensory processing in auditory association cortex: an fMRI study. J Neurophysiol (2002) 2.12
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis (2012) 2.11
3-T direct MR arthrography of the wrist: value of finger trap distraction to assess intrinsic ligament and triangular fibrocartilage complex tears. Eur J Radiol (2013) 2.09
Safe and effective variability-a criterion for dose individualization. Ther Drug Monit (2012) 2.08
How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart (2011) 2.06
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther (2003) 2.05
MR connectomics: Principles and challenges. J Neurosci Methods (2010) 2.02
Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry (2010) 2.02
The role of alprazolam for the treatment of panic disorder in Australia. Aust N Z J Psychiatry (2012) 2.02
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2013) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol (2008) 1.98
A survey of combination antidepressant use in Australia. Australas Psychiatry (2007) 1.98
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.97
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet (2002) 1.96
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem (2005) 1.95
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res (2004) 1.95
Occipital transcranial magnetic stimulation has opposing effects on visual and auditory stimulus detection: implications for multisensory interactions. J Neurosci (2007) 1.94
N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry (2008) 1.93
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord (2009) 1.91
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Maternal and early postnatal nutrition and mental health of offspring by age 5 years: a prospective cohort study. J Am Acad Child Adolesc Psychiatry (2013) 1.87
Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A (2007) 1.80
Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. Br J Psychiatry (2011) 1.77
Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci (2010) 1.74
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry (2008) 1.73
The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta (2013) 1.72
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood (2010) 1.70
Moving towards a population health approach to the primary prevention of common mental disorders. BMC Med (2012) 1.65
Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med (2014) 1.64
The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry (2010) 1.64
A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. J Med Genet (2012) 1.63
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 1.61
The connectome viewer toolkit: an open source framework to manage, analyze, and visualize connectomes. Front Neuroinform (2011) 1.60
Event-related potentials and time course of the "other-race" face classification advantage. Neuroreport (2004) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mapping the human connectome at multiple scales with diffusion spectrum MRI. J Neurosci Methods (2011) 1.56
Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry (2009) 1.56
Relationship between brain perfusion computed tomography variables and cerebral perfusion pressure in severe head trauma patients. Crit Care Med (2004) 1.55
Abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer G protein-coupled receptor 1. PLoS One (2009) 1.55
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord (2007) 1.55
Accuracy of brain multimodal monitoring to detect cerebral hypoperfusion after traumatic brain injury*. Crit Care Med (2015) 1.55
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther (2008) 1.54
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res (2010) 1.53
The association between habitual diet quality and the common mental disorders in community-dwelling adults: the Hordaland Health study. Psychosom Med (2011) 1.52
TORC1 is a calcium- and cAMP-sensitive coincidence detector involved in hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A (2007) 1.52
Multi-phase post-mortem CT angiography: development of a standardized protocol. Int J Legal Med (2010) 1.51
Oxidative pathways as a drug target for the treatment of autism. Expert Opin Ther Targets (2010) 1.51
Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet (2006) 1.50